The Oracle Health Clinical AI Agent is unique in the way it’s embedded directly in the Oracle Health Foundation EHR, making it easier for nurses who don’t have to shift between tools used for separate tasks. The post How is Oracle Health’s Nurse AI Agent Different? appeared first on MedCity News.

Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 results in Sjögren’s disease. This fusion protein could compete against a Novartis antibody under an FDA review that could make it the first Sjögren’s therapy. The post Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds appeared first on MedCity News.

Healthcare leaders know how to test software. We don’t yet have a shared playbook for onboarding agents expected to do a job end to end. That is the gap a probation period is meant to fill. The post AI Workers Need a Probation Period, Not Just a Pilot appeared first on MedCity News.

Telix Pharmaceuticals is acquiring Isotope Technologies Munich, or ITM, in a $1.65 billion stock deal that will create a radiopharmaceuticals company with greater global scale. ITM’s lead pipeline asset is in late-stage development for a type of gastrointestinal cancer, where it could compete against Novartis and Curium Pharma products. The post Radiopharmaceutical Dealmaking Continues With Telix’s $1.65B ITM Acquisition appeared first on MedCity News.

Array Behavioral Care launched a new service to help providers assess patients with urgent behavioral health needs and connect them to appropriate care. The post Array Behavioral Care Unveils New Triage Model appeared first on MedCity News.

Since implementing AI clinical documentation improvement (CDI) tools, Intermountain has seen a 22% point increase in inpatient chart completion during or immediately after rounds. The post How AI Is Transforming Clinical Documentation at Intermountain Health appeared first on MedCity News.

They see the problem first, build the fix, and decide whether it is ever adopted. The market has trained them to hide the one credential that de-risks the deal. The post The Nurse Is Health Care’s Most Underpriced Founder appeared first on MedCity News.

Electra Therapeutics’ IPO cash will support a potential first-in-class drug whose lead indication is a rare hyperinflammatory disorder with no FDA-approved treatments. Meanwhile, clinical-stage biotechs Marea Therapeutics and Sensorion revealed their respective plans to enter the U.S. public markets. The post Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs appeared first on MedCity News.

Angle Health’s funding round was led by Vitruvian Partners, with participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator. The post Angle Health Raises $600M to Grow Employer Health Benefits Platform appeared first on MedCity News.

HHS Secretary Robert F. Kennedy Jr. named eight new members to the U.S. Preventive Services Task Force this week, completing the 16-seat panel amid ongoing tension over its leadership. The post RFK Jr. Overhauls USPSTF Leadership: 5 Things to Know appeared first on MedCity News.

What happened was not just a cybersecurity failure, it was an infrastructure failure. The post Two Years After the Change Healthcare Cyberattack, Healthcare Still Has a Clearinghouse Redundancy Problem appeared first on MedCity News.

This structural problem calls for a structural solution, requiring no new science, regulation, or data.  The post The Trials Were Always There — Patients Just Couldn’t Find Them appeared first on MedCity News.

Ayble Health’s Series A round was led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx and Accomplice. The post Ayble Health Secures $16M for Virtual Digestive Health Clinic appeared first on MedCity News.

Ultragenyx Pharmaceutical’s Fayuvi is now the first FDA-approved therapy for the underlying cause of Sanfilippo syndrome type A, an ultra-rare inherited neurological disorder. It’s the second approved gene therapy for Ultragenyx, which specializes in rare disease medicines. The post Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo appeared first on MedCity News.

CMS will expand its ACCESS model starting in spring 2027 to cover heart failure, COPD, substance use disorders and tobacco cessation. The outcomes-based payment model, which launched in July with 160 participating providers, will now make roughly three in four Medicare beneficiaries eligible for at least one track. The post CMS Broadens ACCESS Model to New Chronic Conditions appeared first on MedCity News.